Longitudinal patterns of urine biomarkers in infants across gestational ages

Marissa J DeFreitas1, Wacharee Seeherunvong2, Chryso P Katsoufis2

  • 1Division of Pediatric Nephrology, University of Miami/ Holtz Children's Hospital, 1611 NW 12th Avenue (Annex 504), Miami, FL, 33136, USA. mdefreitas@med.miami.edu.

Insights

Urinary biomarkers like epidermal growth factor (EGF) and uromodulin (UMOD) change with gestational age in neonates. These developmental patterns help assess normal kidney development in infants.

Area of Science:

  • Neonatal physiology
  • Pediatric nephrology
  • Biomarker research

Background:

  • Urinary biomarkers may indicate acute kidney injury (AKI) but their developmental patterns in healthy neonates are poorly understood.
  • Understanding these patterns is crucial for assessing kidney health in infants across a spectrum of gestational ages.

Purpose of the Study:

  • To investigate the developmental trajectories of seven urinary biomarkers in healthy neonates from birth to three months of age.
  • To characterize how these biomarkers change with advancing gestational age (GA) and post-natal development.

Main Methods:

  • Urine samples were collected from 52 infants (24-41 weeks GA) from birth to 3 months.
  • Assayed for albumin (ALB), beta-2-microglobulin (B2M), cystatin-C (CysC), epidermal growth factor (EGF), neutrophil-gelatinase-associated lipocalin (NGAL), osteopontin (OPN), and uromodulin (UMOD).

Main Results:

  • Epidermal growth factor (EGF) and uromodulin (UMOD) increased with advancing GA and post-natal age.
  • By 3 months, preterm infants' EGF and UMOD levels reached those of term infants.
  • EGF and UMOD showed potential for distinguishing estimated glomerular filtration rate (GFR) <30 ml/min/1.73 m², while cystatin-C/creatinine and albumin/creatinine were significant functional markers.

Conclusions:

  • Urinary biomarker levels significantly vary with gestational age in healthy neonates.
  • These findings support the utility of urinary biomarkers for monitoring normal kidney development in infants.
  • Specific biomarkers like EGF and UMOD can track kidney maturation and function in the neonatal period.
Abstract

Related Concept Videos

Urine Studies I: Urinalysis01:29

Urine Studies I: Urinalysis

Urinalysis is a widely used diagnostic test that analyzes urine's physical, chemical, and microscopic characteristics. Healthcare providers use it to detect and monitor various health conditions, including renal disease, urinary tract infections (UTIs), diabetes, and metabolic or systemic disorders.Components of UrinalysisUrinalysis consists of three primary components: physical, chemical, and microscopic examination. Each provides unique insights into the urine sample and, by extension, the...
2.1K
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
327
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
693
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
369
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
458
Development of the Oral Microbiota01:28

Development of the Oral Microbiota

The establishment of the oral microbiome begins before birth, challenging the long-held belief that the fetal oral cavity is sterile. The presence of oral microbes such as Streptococcus and Fusobacterium in amniotic fluid suggests that microbial exposure may occur in utero, potentially through translocation from the maternal oral or gastrointestinal tract. This early colonization primes the neonatal immune system and sets the stage for subsequent microbial succession. Maternal health,...
19